Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access will find a wealth of contextualized life science insight ready to be viewed in the FENIX Marketplace.
Welcome to FENIX Syndicated Services. If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.
$599
Posted in: Other Aug 09 | 2023Terns Announces Positive Topline Ph2a NASH Data; Ionis Q2 ’23 EarningsPurchase Blast
$599
Posted in: Glucagon, Glucose Monitoring, Insulin Delivery, Other, SGLT2i Aug 09 | 2023Insulet, Xeris, Madrigal, and Bayer Q2 ‘23 EarningsPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucagon, SGLT2i Aug 08 | 2023Lilly Up Big Following Q2 ’23 Results and SELECT Data ReadoutPurchase Blast
$599
Posted in: GLP-1RA, Other Aug 08 | 2023Novo and Lilly Win with Positive SELECT CVOT Topline ResultsPurchase Blast
$599
Posted in: GLP-1RA, Insulin Delivery Aug 07 | 2023MannKind and Viatris Q2 ’23 Earnings UpdatesPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Glucagon, Glucose Monitoring, Insulin Delivery, Other, SGLT2i Aug 04 | 2023Tandem, Lexicon, and Amgen Q2 ‘23 EarningsPurchase Blast
$599
Posted in: GLP-1RA, Glucagon, Other Aug 03 | 2023Alnylam and Regeneron Q2 ’23 Earnings; Ionis and Novartis Partner for New Lp(a) Therapy; NeuroBo Receives IRB Approval for Ph2a DA-1241 Study in NASHPurchase Blast
$599
Posted in: DPP-IVi, Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, SGLT2i Aug 02 | 2023Lilly Initiates Additional Ph3 Orforglipron Trial; Mounjaro Label Update; Vertex, Amarin, and Intercept Q2 ‘23 Earnings; Glenmark Receives ANDA Approval for 2.5mg and 5mg Saxagliptin; Dario Introduces GLP-1RA Obesity Program; Tandem Initiates Sigi Patch Pump TrialPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucagon, Other Aug 01 | 2023Altimmune Initiates Ph2b Pemvidutide NASH Trial; Pfizer, Esperion, and Merck Q2 ‘23 EarningsPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other Aug 01 | 2023Afon to Launch Non-Invasive Blood Glucose Sensor in 2024; DEKA ACE Pump Receives 510(k) Clearance; Novo Nordisk Launches Wegovy in Germany; Ionis Completes CARDIO-TTRansform EnrollmentPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucagon, Glucose Monitoring, Other Jul 28 | 2023Lilly Completes Tirzepatide Obesity Trials; Teladoc, Viking, and Roche Q2 ‘23 EarningsPurchase Blast
$599
Posted in: GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, SGLT2i Jul 25 | 2023Wegovy Label Update; Jardiance Receives EMPA-KIDNEY Approval in EU; Glucotrack Announces Positive Implantable CGM Data; Thane Wettig Succeeds Enrique Conterno as Fibrogen CEOPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Other Jul 24 | 2023Biocon Receives Even More Form 483 Observations; Roche and Alnylam Partner for Hypertension RNAi; Dario Issues Preliminary Q2 ’23 Results and Business UpdatePurchase Blast
$599
Posted in: Basal Insulin, Glucose Monitoring, Insulin Delivery, Other Jul 21 | 2023Abbott Q2 ’23 Earnings; Merck Initiates Ph3 Oral PCSK9i Program; Pfizer Partners with Riparian for CV Development; Amarin Corporate Updates; J&J Q2 ’23 EarningsPurchase Blast
$599
Posted in: Other Jul 18 | 2023Novartis Discontinues Ph2 Obesity Asset; Novartis Q2 ‘23 Earnings; Akebia to Resubmit Vadadustat NDAPurchase Blast
$599
Posted in: Basal Insulin, Dual/triple agonist, GLP-1RA, Other, SGLT2i Jul 17 | 2023Novo and Eleven Therapeutics Collaborate for Nucleic Acid Therapeutics; July CHMP Agenda; Madrigal Completes Resmetirom NDA Submission; Capital Health Partners with Virta Health for Rx Reverse LaunchPurchase Blast
$599
Posted in: GLP-1RA, Glucose Monitoring, Other, SGLT2i Jul 14 | 2023Lilly to Acquire Versanis Bio; Brenzavvy Available by Prescription at Mark Cuban Cost Plus Drug Company; Abbott Initiates Libre 3 trial in T2DM and Basal Therapy; Nemaura FY ‘22 Earnings UpdatePurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Glucose Monitoring, Insulin Delivery, Other Jul 12 | 2023Tandem Mobi Receives FDA Clearance; Better Therapeutics’s AspyreRx Receives FDA Authorization for T2DMPurchase Blast